Showing 2221-2230 of 5957 results for "".
- Tarsus Partners With John Cena on Demodex Blepharitis Awareness Campaignhttps://modernod.com/news/tarsus-partners-with-john-cena-on-demodex-blepharitis-awareness-campaign/2487094/Tarsus Pharmaceuticals is partnering with celebrity John Cena on a campaign to raise awareness of Demodex blepharitis. As part of this campaign, Cena will detail his own experience with Demodex blepharitis and lotilaner ophthalmic solution 0.25% (Xdemvy) the first FDA-approved t
- SightGlass Vision Reports on 2-Year Chinese Study for DOT Spectacle Lenses for Myopiahttps://modernod.com/news/sightglass-vision-reports-on-2-year-chinese-study-for-dot-spectacle-lenses-for-myopia/2486985/Key Takeaways SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
- Haag-Streit USA, Marco Lombart Sign Exclusive US Distribution Deal for Diagnostic Platformshttps://modernod.com/news/haag-streit-usa-marco-lombart-sign-exclusive-us-distribution-deal-for-diagnostic-platforms/2486763/Haag-Streit USA and Marco Lombart have entered into an exclusive distribution agreement for the Lenstar 900 optical biometer and the Octopus 600 and Octopus 900 perimeters in the United States. Under the agreement, Marco Lomb
- BostonSight Expands Scleral Lens Portfolio with New Smaller Diameter Optionshttps://modernod.com/news/bostonsight-expands-scleral-lens-portfolio-with-new-smaller-diameter-options/2486629/Key Takeaways BostonSight introduced three new smaller BostonSight Scleral lens diameters available in a single FitKit for both eyes
- CooperVision Launches ‘Made Better Promise’ to Advance Sustainability in Contact Lenseshttps://modernod.com/news/coopervision-launches-made-better-promise-to-advance-sustainability-in-contact-lenses/2486576/Key Takeaways CooperVision launched the Made Better Promise, a global sustainability platform embedded across the lifecycle of its contact lens products, starting with MyDay.
- IDOC Launches Easyvision Private Label Contact Lens Portfolio for Independent Optometristshttps://modernod.com/news/idoc-launches-easyvision-private-label-contact-lens-portfolio-for-independent-optometrists/2486489/Key Takeaways easyvision is a new private label daily disposable contact lens portfolio from IDOC, manufactured by CooperVision
- SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurityhttps://modernod.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486398/Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- Study Finds GLP-1 Drugs Linked to Lower Risk of Legal Blindness in Type 2 Diabeteshttps://modernod.com/news/study-finds-glp-1-drugs-linked-to-lower-risk-of-legal-blindness-in-type-2-diabetes/2486332/A large real-world study suggests that widely used GLP-1 receptor agonists—commonly prescribed for type 2 diabetes and weight management—may significantly reduce the risk of legal blindness in high-risk patients. The research,
- FDA Issues Third Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalaphttps://modernod.com/news/fda-issues-third-complete-response-letter-to-aldeyra-therapeutics-for-dry-eye-drug-reproxalap/2486097/In another setback for Aldeyra Therapeutics, the FDA issued a third Complete Response Letter (CRL) regarding its new drug application (NDA) for investigational dry eye treatment reproxalap. In the letter, the FDA stated that th